Bristol-Myers Squibb’s acquisition of Inhibitex – a biopharmaceutical company

Bristol-Myers Squibb

Bristol-Myers Squibb Co. has announced the acquisition of Inhibitex Inc. – the company focusing primarily on drugs for infections – for almost $2.5billion as a business strategy “for long term growth potential” and to expand its developmental approaches of antiviral drugs and therapeutic strategies for infectious diseases.

According to the company, both the boards have approved the transaction. Moreover, Inhibitex reported that its shareholders agreed on an offer of $26 per share i.e. more than double its closing price of $9.87 on January 6.

“The acquisition of Inhibitex builds on Bristol-Myers Squibb’s long history of discovering, developing and delivering innovative new medicines in virology and enriches our portfolio of investigational medicines for hepatitis C,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “There is significant unmet medical need in hepatitis C. This acquisition represents an important investment in the long-term growth of the company.”

“This transaction puts INX-189 and the Company’s other infectious disease assets in the hands of an organization that can more optimally develop them and which believes as strongly as we do in INX-189’s potential in the treatment of chronic HCV,” said Russell Plumb, President and Chief Executive Officer of Inhibitex. “Bristol-Myers Squibb’s expertise in antiviral drug development, and its existing complementary portfolio, will assure that the potential of INX-189 is realized as part of future oral combination therapies for millions of patients in need around the world.”

“Bristol-Myers Squibb continues to drive advances in the field of hepatitis C research and development through internal development and selective partnerships,” said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, R&D, Bristol-Myers Squibb. “The addition of Inhibitex’s nucleotide polymerase inhibitor to our own promising portfolio, which includes other direct-acting antivirals, brings additional options to develop all-oral regimens with better cure rates, shorter duration of therapy and lower toxicity than the current standard of care.”

According to the company,

The transaction is expected to be dilutive to earnings for Bristol-Myers Squibb through 2016, with an expected impact on earnings per share of approximately $0.04 in 2012 and approximately $0.05 in 2013.

saypeople

SayPeople.com gives you the news and information about Science, Research, Technology, Business and Islam.

%d bloggers like this: